Home/Iterum Therapeutics/Christine R. Coyne
CR

Christine R. Coyne

Chief Commercial Officer

Iterum Therapeutics

Iterum Therapeutics Pipeline

DrugIndicationPhase
ORLYNVAH™ (sulopenem)Uncomplicated Urinary Tract Infection (uUTI)Approved